Fresh analysis reveals that people who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Findings released in a leading health publication shows that while obese people often shed substantial amounts of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Users purchasing such treatments should be aware of the risk of rapid weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass in about a year and a half.
Comparing Approaches
The study, which looked at 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through dieting generally experience a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Experts propose the mode of action of the injections explains the accelerated regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals argue that, considering the high risk of relapse, the treatment should be considered long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," similar to managing conditions like diabetes.
Patient Accounts
Users who have come off the medication describe a powerful resurgence of appetite.
"It felt as if a trigger activating and you become starving," said an individual.
The struggle is exacerbated if users have not developed permanent lifestyle or habit changes during treatment.
Significant Use
Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while these medications are potent tools for weight loss, they are not a standalone solution and lasting health benefits relies on combined lifestyle management.
